Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium. Province MA, et al. Among authors: lambrechts d. Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23. Clin Pharmacol Ther. 2014. PMID: 24060820 Free PMC article.
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D, Billen J, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Weltens C, Van Limbergen E, Van den Bogaert W, Vergote I, Van Huffel S, Christiaens MR, Neven P. Dieudonné AS, et al. Among authors: lambrechts d. Breast Cancer Res Treat. 2009 Dec;118(3):531-8. doi: 10.1007/s10549-009-0463-5. Epub 2009 Jul 12. Breast Cancer Res Treat. 2009. PMID: 19597703
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H. Vulsteke C, et al. Among authors: lambrechts d. Ann Oncol. 2013 Jun;24(6):1513-25. doi: 10.1093/annonc/mdt008. Epub 2013 Feb 7. Ann Oncol. 2013. PMID: 23396606 Free article.
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Peeters M, van Dam P, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H. Vulsteke C, et al. Among authors: lambrechts d. Breast Cancer Res Treat. 2014 Oct;147(3):557-70. doi: 10.1007/s10549-014-3105-5. Epub 2014 Aug 29. Breast Cancer Res Treat. 2014. PMID: 25168315 Clinical Trial.
Common germline polymorphisms associated with breast cancer-specific survival.
Pirie A, Guo Q, Kraft P, Canisius S, Eccles DM, Rahman N, Nevanlinna H, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J, Michailidou K, Lush M, Dunning AM, Shah M, Czene K, Darabi H, Eriksson M, Lambrechts D, Weltens C, Leunen K, van Ongeval C, Nordestgaard BG, Nielsen SF, Flyger H, Rudolph A, Seibold P, Flesch-Janys D, Blomqvist C, Aittomäki K, Fagerholm R, Muranen TA, Olsen JE, Hallberg E, Vachon C, Knight JA, Glendon G, Mulligan AM, Broeks A, Cornelissen S, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Cross SS, Reed MW, Giles GG, Milne RL, McLean C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Hooning MJ, Hollestelle A, Martens JW, van den Ouweland AM, Marme F, Schneeweiss A, Yang R, Burwinkel B, Figueroa J, Chanock SJ, Lissowska J, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Brenner H, Butterbach K, Holleczek B, Kataja V, Kosma VM, Hartikainen JM, Li J, Brand JS, Humphreys K, Devilee P, Tollenaar RA, Seynaeve C, Radice P, Peterlongo P, Manoukian S, Ficarazzi F, Beckmann MW, Hein A, Ekici AB, Balleine R, Phillips KA; kConFab Investigators; Benitez J, Zamora MP, Perez JI, Menéndez P, Jakubowska A, Lubinski … See abstract for full author list ➔ Pirie A, et al. Among authors: lambrechts d. Breast Cancer Res. 2015 Apr 22;17(1):58. doi: 10.1186/s13058-015-0570-7. Breast Cancer Res. 2015. PMID: 25897948 Free PMC article.
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.
Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE; Australian Ovarian Cancer Study Group; Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Goodman MT, Ness RB, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode EL, Vierkant RA, Larson MC, Fridley BL, Høgdall C, Schildkraut JM, Weber RP, Cramer DW, Terry KL, Bandera EV, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang HP, Brinton LA, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Webb PM; Ovarian Cancer Association Consortium. Nagle CM, et al. Among authors: lambrechts s, lambrechts d. Br J Cancer. 2015 Sep 1;113(5):817-26. doi: 10.1038/bjc.2015.245. Epub 2015 Jul 7. Br J Cancer. 2015. PMID: 26151456 Free PMC article.
605 results